Ntla-2001
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Intellia TherapeuticsPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Transthyretin Amyloidosis (ATTR) With Cardiomyopathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Patisiran Alnylam Pharmaceuticals | Phase 3 | BB |
Aln-Ttrsc02 Alnylam Pharmaceuticals | Phase 3 | B |
Same molecule, other indications
Ntla-2001 is also rated in:
Transthyretin-Related (ATTR) Familial Amyloid PolyneuropathyDormant
CC
Indicative ·
47 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →